Stuart P Adler1, Anne-Marie Manganello1, Ronzo Lee2, Michael A McVoy2, Daniel E Nixon3, Stanley Plotkin4,5, Edward Mocarski6, Josephine H Cox7, Patricia E Fast7, Pavlo A Nesterenko8, Susan E Murray8,9, Ann B Hill8, George Kemble10. 1. CMV Research Foundation. 2. Department of Pediatrics. 3. Department of Internal Medicine, Virginia Commonwealth University, Richmond. 4. University of Pennsylvania. 5. Wistar Institute, Philadelphia, Pennsylvania. 6. Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, Georgia. 7. International AIDS Vaccine Initiative, New York. 8. Department of Molecular Microbiology and Immunology, Oregon Health and Science University. 9. Department of Biology, University of Portland, Oregon. 10. 3-V Biosciences, Menlo Park, California.
Abstract
BACKGROUND: Human cytomegalovirus (HCMV) infection causes disease in newborns and transplant recipients. A HCMV vaccine (Towne) protects transplant recipients. METHODS: The genomes of Towne and the nonattenuated Toledo strain were recombined, yielding 4 Towne/Toledo chimera vaccines. Each of 36 HCMV-seronegative men received 1 subcutaneous dose of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3. Safety and immunogenicity were evaluated over 12 weeks after immunization and for 52 weeks for those who seroconverted. RESULTS: There were no serious local or systemic reactions. No subject had HCMV in urine or saliva. For chimera 3, none of 9 subjects seroconverted. For chimera 1, 1 of 9 seroconverted (the seroconverter received 100 PFU). For chimera 2, 3 subjects seroconverted (1 received 100 PFU, and 2 received 1000 PFU). For chimera 4, 7 subjects seroconverted (1 received 10 PFU, 3 received 100 PFU, and 3 received 1000 PFU). All 11 seroconverters developed low but detectable levels of neutralizing activity. CD4+ T-cell responses were detectable in 1 subject (who received 100 PFU of chimera 4). Seven subjects receiving chimera 2 or 4 had detectable CD8+ T-cell responses to IE1; 3 responded to 1-2 additional antigens. CONCLUSIONS: The Towne/Toledo chimera vaccine candidates were well tolerated and were not excreted. Additional human trials of chimeras 2 and 4 are appropriate. CLINICAL TRIALS REGISTRATION: NCT01195571.
BACKGROUND:Human cytomegalovirus (HCMV) infection causes disease in newborns and transplant recipients. A HCMV vaccine (Towne) protects transplant recipients. METHODS: The genomes of Towne and the nonattenuated Toledo strain were recombined, yielding 4 Towne/Toledo chimera vaccines. Each of 36 HCMV-seronegative men received 1 subcutaneous dose of 10, 100, or 1000 plaque-forming units (PFU) in cohorts of 3. Safety and immunogenicity were evaluated over 12 weeks after immunization and for 52 weeks for those who seroconverted. RESULTS: There were no serious local or systemic reactions. No subject had HCMV in urine or saliva. For chimera 3, none of 9 subjects seroconverted. For chimera 1, 1 of 9 seroconverted (the seroconverter received 100 PFU). For chimera 2, 3 subjects seroconverted (1 received 100 PFU, and 2 received 1000 PFU). For chimera 4, 7 subjects seroconverted (1 received 10 PFU, 3 received 100 PFU, and 3 received 1000 PFU). All 11 seroconverters developed low but detectable levels of neutralizing activity. CD4+ T-cell responses were detectable in 1 subject (who received 100 PFU of chimera 4). Seven subjects receiving chimera 2 or 4 had detectable CD8+ T-cell responses to IE1; 3 responded to 1-2 additional antigens. CONCLUSIONS: The Towne/Toledo chimera vaccine candidates were well tolerated and were not excreted. Additional human trials of chimeras 2 and 4 are appropriate. CLINICAL TRIALS REGISTRATION: NCT01195571.
Authors: S A Plotkin; S E Starr; H M Friedman; K Brayman; S Harris; S Jackson; N B Tustin; R Grossman; D Dafoe; C Barker Journal: Ann Intern Med Date: 1991-04-01 Impact factor: 25.391
Authors: Peter Tomasec; Eddie C Y Wang; Andrew J Davison; Borivoj Vojtesek; Melanie Armstrong; Cora Griffin; Brian P McSharry; Rebecca J Morris; Sian Llewellyn-Lacey; Carole Rickards; Akio Nomoto; Christian Sinzger; Gavin W G Wilkinson Journal: Nat Immunol Date: 2005-01-09 Impact factor: 25.606
Authors: Emily E Marshall; Daniel Malouli; Scott G Hansen; Roxanne M Gilbride; Colette M Hughes; Abigail B Ventura; Emily Ainslie; Andrea N Selseth; Julia C Ford; David Burke; Craig N Kreklywich; Jennie Womack; Alfred W Legasse; Michael K Axthelm; Christoph Kahl; Daniel Streblow; Paul T Edlefsen; Louis J Picker; Klaus Früh Journal: Sci Transl Med Date: 2019-07-17 Impact factor: 17.956
Authors: Nicolás M Suárez; Betty Lau; George M Kemble; Ronzo Lee; Edward S Mocarski; Gavin W G Wilkinson; Stuart P Adler; Michael A McVoy; Andrew J Davison Journal: Virus Genes Date: 2017-04-08 Impact factor: 2.332